Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRON-HFpEF: Ferric carboxymaltose in heart failure with preserved ejection fraction and iron deficiency
2019-003461-17Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ferric carboxymaltose in heart failure with preserved ejection fraction (HFpEF), sponsored by Amsterdam University Medical Center. Primary endpoint: Exercise PCWP. Started Oct 2019; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2019-003461-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003461-17.